H1 2021 results

Greg Poux-Guillaume, CEO | Jill Lee, CFO | July 22, 2021
IMPORTANT

The presentation has been prepared by Sulzer Ltd. ("Sulzer", and together with its subsidiaries, the "Sulzer Group") and the Applicator System ("APS") division of the Sulzer Group to be spun off and re-named medmix ("medmix") for information and background purposes only. This document is not, and should not be construed as, a prospectus or offering document, and has not been reviewed or approved by any regulatory or supervisory authority. The information does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or a solicitation or invitation of any offer to subscribe for or purchase any loans or securities of or make an investment in Sulzer or any member of the Sulzer Group or medmix or any of its subsidiaries or any other entity in any jurisdiction, and nothing contained therein shall form the basis of, or be relied on in connection with, any contract or commitment whatsoever, in particular, it must not be used in making any investment decision. Any decision to invest in securities should be made on the basis of the information to be contained in a prospectus and on an independent analysis of the information contained therein.

This presentation includes financial information which has been derived from the historical combined and carve-out financial statements of medmix for the years 2018, 2019 and 2020 (the "Relevant Period") (the "Combined and Carve-out Financial Statements"), which are currently in draft form and unaudited and therefore continue to be subject to change prior to completion of the audit and release of the related audit report. While the Combined and Carve-out Financial Statements have been prepared on a carve-out basis from the consolidated financial statements of Sulzer, their preparation required that certain changes be made to the financial information as presented for the APS division in Sulzer’s consolidated financial statements for the Relevant Period. Accordingly, the financial information derived from the draft Combined and Carve-out Financial Statements of medmix for the Relevant Period and from the consolidated financial statements of Sulzer is not fully comparable. The APS division also includes certain quarterly information of medmix for the year 2020 and the first quarter of 2021, which has not been subject to an audit or audit review and may be subject to change. Certain financial data included in this presentation consists of non-IFRS financial measures. These non-IFRS financial measures may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other financial measures determined in accordance with IFRS.

No representation, warranty or undertaking, express or implied, is made by Sulzer, medmix or any of their respective affiliates or directors, officers, employees, agents or advisers ("Representatives") or any other person as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein or any other statement made or purported to be made in connection with Sulzer, the Sulzer Group or medmix or any of its subsidiaries, for any purpose whatsoever, including but not limited to any investment considerations. No responsibility, obligation or liability whatsoever, whether arising in tort, contract or otherwise, is or will be accepted by Sulzer, medmix or any of their respective Representatives or any other person for any loss, cost or damage howsoever arising from any use of the Information, or for information or opinions or for any errors, omissions or misstatements contained therein or otherwise arising in connection therewith.

This presentation includes market share and industry data obtained by Sulzer from official or third-party sources. Sulzer may not have access to the facts and assumptions underlying the numerical data, market data and other information extracted from public sources. Third-party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. Neither Sulzer, medmix nor any of their respective Representatives or any other person are able to verify such information, and assume no responsibility for the correctness of any such information. In addition, certain of the industry and market data included in this presentation, if not labelled otherwise, are derived from Sulzer’s internal research and estimates based on the knowledge and experience of its management in the markets in which it operates. Accordingly, no undue reliance should be placed on any of the numerical or market data contained in this presentation.

This presentation contains forward-looking statements, including but not limited to, projections of financial developments, market activities, future performance of products and solutions or planned transactions, which involve risks and uncertainties and are based on certain assumptions. The forward-looking statements are subject to change based on known or unknown risks and various other factors, which could cause the actual results, performance or events to differ materially from the statements made herein. If any of these risks and uncertainties materializes or if the assumptions underlying any of Sulzer's or medmix' forward-looking statements prove to be incorrect, the actual results may be materially different from those Sulzer or medmix express or imply by such statements. Neither Sulzer nor medmix intend or assume any obligation to update or correct any forward-looking statements when they are expected solely on the circumstances at the date of their publication.

This presentation constitutes neither an offer to sell nor a solicitation to buy securities. This presentation shall also not be considered as a prospectus or similar notice in accordance with article 35 et seqq. FinSA and/or article 69 FinSA. Any offer and listing of securities shall be made exclusively by and based on a securities prospectus to be published. Any investment decision regarding publicly offered securities shall only be made based on the securities prospectus. Any offering of securities mentioned herein will not be registered under the United States Securities Act of 1933, as amended (the "Act"), and such securities may not be offered or sold in the United States of America absent registration or an applicable exemption from registration requirements under the Act. This presentation is not a prospectus for the purposes of Regulation (EU) 2017/1129 as amended, the "Prospectus Regulation". Any offer of securities in any Member State of the European Economic Area will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of securities. Any offering of securities mentioned herein will not be registered under the United States Securities Act of 1933, as amended (the "Act"), and such securities may not be offered or sold in the United States of America absent registration or an applicable exemption from registration requirements under the Act. This presentation is not a prospectus for the purposes of Regulation (EU) 2017/1129 as it forms part of domestic law pursuant to the European Union (Withdrawal) Act 2018 (the "UK Prospectus Regulation"). Any offer of securities in the United Kingdom will be made pursuant to an exemption under the UK Prospectus Regulation from the requirement to publish a prospectus for offers of securities.

In addition, in the United Kingdom, this presentation is being made, and is directed only at (i) persons falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act (Financial Promotion) Order 2005 (as amended, the "Order")), (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order, (iii) persons falling within Article 49(2)(b) of the Order, including existing members and creditors of Sulzer or, (iv) persons, fiduciaries or investment officers of any employee benefit plan which has total assets in excess of $50 million or, (v) persons, fiduciaries or investment officers of any employee benefit plan with the plan having 100 or more participants or beneficiaries or (vi) persons, fiduciaries or investment officers of any employee benefit plan with total assets in excess of $50 million. Persons who are not investment professionals should not act or rely on this presentation or any related documents and/or materials or any of its or their contents.

Note on Alternative Performance Measures (APM): all bridges from APM to reported figures can be found in the financial section of Sulzer's half-year report 2021.
Business Review
H1 2021 highlights

- Orders up 12% (+7% organic) in Q2 YOY, +8% sequentially
- Sales up 9% (6% organic) in H1 YOY
- Operational Profitability reached 10.0% in H1, up 250 bps YOY
- FCF tripled YOY to reach H1 record CHF117m
- Addition of Nordic Water gives Sulzer one of the broadest range of water pumping and treatment solutions
- Applicator Systems division spin off to shareholders announced, to be renamed medmix and listed separately on SIX
- Split will enable Sulzer and medmix to leverage the full potential of each business to maximize profitable growth
H1 2021 Orders and Profit split

Positive trends in all divisions

**Highlights**

- Service (RES): order continue to show positive momentum, sales and profitability above last year
- Pumps (PE): strong order growth in Water (> 40% of PE), Industry robust, Energy at trough
- Chemtech (CT): growth on all metrics. Renewables business continues to show momentum
- Applicators (APS): high performing Dental and Industry segments, first customer for new D-Flex platform in Drug Delivery
Pumps Equipment (PE)
Water and Industry dynamic, Energy at trough, sustained profitability momentum

**Key figures**

<table>
<thead>
<tr>
<th>In CHF millions</th>
<th>H1 21</th>
<th>H1 20</th>
<th>YOY</th>
<th>adj.¹</th>
<th>org.²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Order intake</td>
<td>627</td>
<td>744</td>
<td>-15.8%</td>
<td>-15.3%</td>
<td>-20.2%</td>
</tr>
<tr>
<td>Sales</td>
<td>664</td>
<td>617</td>
<td>7.7%</td>
<td>8.8%</td>
<td>4.4%</td>
</tr>
<tr>
<td>EBIT</td>
<td>15</td>
<td>-27</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operational profit (opEBITA)</td>
<td>33</td>
<td>19</td>
<td>72.9%</td>
<td>70.5%</td>
<td>56.8%</td>
</tr>
<tr>
<td>operational profitability</td>
<td>5.0%</td>
<td>3.1%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Order intake by segment**

- Energy: 28%
- Water: 41%
- Industry: 31%

**Highlights**

- Orders:
  - Water up 25% (7% organic), now largest segment within PE
  - Industry up 6%
  - Energy down 50% as anticipated on soft markets and continued selectivity

- Sales up 9% (4.4% organic), driven by Water and Industry

- Operational profitability up to 5.0% on good execution, savings from structural cost actions and favorable mix

- Acquisition of Nordic Water

1. Adjusted for currency effects
2. Organic: adjusted for currency and acquisition effects
Pumps and mixers for new bioproduct mill in Finland

Major project win for Industry

- Frame agreement to supply more than 400 pumps and agitators for the Metsä Fibre plant in Finland, at 1.5 million tons per year the largest wood-based bioproduct mill in the northern hemisphere (under construction)
- The bioproduct mill will be a global leader in environmental, energy and material efficiency. It will operate completely without fossil fuels.
- Sulzer is a leader in flow control solutions for wood-based bioproducts
- We were selected because of our extensive experience in energy efficient pumping and mixing solutions
Rotating Equipment Services (RES)
Orders trending up, strong improvement in profitability

Key figures

<table>
<thead>
<tr>
<th>In CHF millions</th>
<th>H1 21</th>
<th>H1 20</th>
<th>YOY</th>
<th>adj.¹</th>
<th>org.²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Order intake</td>
<td>571</td>
<td>617</td>
<td>-7.5%</td>
<td>-5.6%</td>
<td>-6.0%</td>
</tr>
<tr>
<td>Sales</td>
<td>526</td>
<td>528</td>
<td>-0.5%</td>
<td>1.3%</td>
<td>0.9%</td>
</tr>
<tr>
<td>EBIT</td>
<td>66</td>
<td>51</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operational profit (opEBITA)</td>
<td>70</td>
<td>64</td>
<td>9.8%</td>
<td>11.3%</td>
<td>10.7%</td>
</tr>
</tbody>
</table>

operational profitability 13.4% 12.1%

Highlights

- Orders continued positive trend, up 7% sequentially in Q2 (after +10% in Q1), orders down 6% YOY in H1 on record high base and project postponements
- Sales increased in all regions
- Operational profitability up on strong execution and cost discipline

Order intake by segment

- Other Equipment 47%
- Pumps Services 53%

1. Adjusted for currency effects
2. Organic: adjusted for currency and acquisition effects
Shore-to-ship solution upgrade to lower CO2 emissions

Sulzer a leader in sustainability-driven upgrades

- RES received a CHF 6m order from a Sydney harbor owner to upgrade the rotating frequency converter from 3MVA to 5MVA
- The rotating frequency converter is part of the harbor’s shore-to-ship electricity supply system
- Shore-to-ship power supply helps reduce CO2 emissions as it powers ships with electricity from the power grid instead of from on-board diesel generators
- The upgrade is expected to save more than 5’000 tons CO2 per year.
Chemtech (CT)

Chemical market active, renewable technologies gaining traction, strong profitability

Key figures

<table>
<thead>
<tr>
<th></th>
<th>H1 21</th>
<th>H1 20</th>
<th>YOY</th>
<th>adj.¹</th>
<th>org.²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Order intake</td>
<td>354</td>
<td>319</td>
<td>10.8%</td>
<td>12.8%</td>
<td>12.8%</td>
</tr>
<tr>
<td>Sales</td>
<td>306</td>
<td>288</td>
<td>6.2%</td>
<td>7.7%</td>
<td>7.7%</td>
</tr>
<tr>
<td>EBIT</td>
<td>21</td>
<td>11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operational profit (opEBITA)</td>
<td>28</td>
<td>23</td>
<td>20.3%</td>
<td>20.2%</td>
<td>20.2%</td>
</tr>
<tr>
<td>operational profitability</td>
<td>9.1%</td>
<td>8.0%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Highlights

- Orders up 13% driven by recovery in Americas and EMEA and continued growth in Asia (on already very high base)
- Renewables in H1 21 almost at FY 20 level
- Tower Field Services rebounding as travel normalizes
- Operational profitability up on structural cost savings

1. Adjusted for currency effects
2. Organic: adjusted for currency and acquisition effects
Partnership with Blue Planet to reduce CO2 emissions
Chemtech carbon capture solution helps lower emissions from cement industry

▪ Sulzer is enabling the further development and optimization of Blue Planet’s innovative carbon mineralization process for carbon capture, utilization and storage (CCUS) solutions.

▪ Blue Planet’s technology uses CO2 as a raw material for making carbonate rocks. The carbonate rocks produced can substitute natural limestone rock mined from quarries. Limestone is the principal component of concrete.

▪ Chemtech’s highly efficient and effective carbon capture unit will be a key enabler in Blue Planet’s pilot plant, which is being constructed in Pittsburg, California, USA.
Applicator Systems (APS)

Strong recovery in Dental and Industry, profitability nearing pre-pandemic level

Key figures

<table>
<thead>
<tr>
<th>In CHF millions</th>
<th>H1 21</th>
<th>H1 20</th>
<th>YOY</th>
<th>adj.¹</th>
<th>org.²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Order intake</td>
<td>269</td>
<td>160</td>
<td>67.9%</td>
<td>69.4%</td>
<td>53.3%</td>
</tr>
<tr>
<td>Sales</td>
<td>228</td>
<td>166</td>
<td>37.5%</td>
<td>38.4%</td>
<td>25.8%</td>
</tr>
<tr>
<td>EBIT</td>
<td>31</td>
<td>9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operational profit (opEBITA)</td>
<td>44</td>
<td>20</td>
<td>126%</td>
<td>128%</td>
<td>109%</td>
</tr>
<tr>
<td>operational profitability</td>
<td>19.3%</td>
<td>11.8%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Highlights

- Volumes up strongly on demand recovery, customer restocking, pent-up demand and market-share gain, particularly in Dental and Industry. Beauty recovery slower (masks, lockdowns, less travel), project pipeline strong
- Drug Delivery: first customer for our new D-Flex pen platform secured, US biotech company placed initial CHF 9m order
- Operational profitability up 750 bps on volume recovery and favorable mix effects
- APS spin-off as medmix planned for end Q3

Order intake by segment

1. Adjusted for currency effects
2. Organic: adjusted for currency and acquisition effects
Commercial win for ecopaCC™

APS sustainable solutions gaining traction

- Applicator Systems has secured two new customers in the Chinese construction market thanks to its award winning ecopaCC™ collapsible cartridge for industry
- The revolutionary design slashes costs, resources and waste, with significant savings potential across the value chain from transportation to disposal
- ecopaCC™ has won the world’s most prestigious packaging innovation competition in the “Resource efficiency” category in 2019
- ecopaCC™ reduces waste by 80%
Financial Review
Overview
Sales growth, strong execution and cost actions result in higher profit margins

Key figures

<table>
<thead>
<tr>
<th>In CHF millions</th>
<th>H1 21</th>
<th>H1 20</th>
<th>YOY</th>
<th>adj.¹</th>
<th>org.²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Order intake</td>
<td>1'820</td>
<td>1'841</td>
<td>-1.1%</td>
<td>0.2%</td>
<td>-3.3%</td>
</tr>
<tr>
<td>Order intake gross margin</td>
<td>35.3%</td>
<td>33.3%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Order backlog (June 30)</td>
<td>1'949</td>
<td>1'946</td>
<td>0.1%</td>
<td>-1.5%</td>
<td></td>
</tr>
<tr>
<td>Sales</td>
<td>1'723</td>
<td>1'599</td>
<td>7.8%</td>
<td>9.2%</td>
<td>6.1%</td>
</tr>
<tr>
<td>Operational profit (opEBITA)</td>
<td>172</td>
<td>120</td>
<td>42.8%</td>
<td>43.5%</td>
<td>38.0%</td>
</tr>
<tr>
<td>Operational profitability</td>
<td>10.0%</td>
<td>7.5%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBIT</td>
<td>129</td>
<td>36</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROS %</td>
<td>7.5%</td>
<td>2.3%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Core net income</td>
<td>119</td>
<td>82</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Core EPS (in CHF)</td>
<td>3.5</td>
<td>2.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Free cash flow</td>
<td>117</td>
<td>37</td>
<td>+218%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FTEs (June 30)</td>
<td>15'574</td>
<td>15'600</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Comment

- Order intake in Q2 up 12% YOY (7% organic) and 8% sequentially on continued market rebound
- Gross margin up on favorable mix
- Sales up on strong backlog entering the year and continued market recovery
- Operational profitability up 250bps due to higher volumes, good execution and favorable mix
- EBIT in H1 20 was impacted by restructuring charge taken for Energy resizing
- Free cash flow on record high for H1

1. Adjusted for currency effects
2. Organic: adjusted for currency and acquisition effects
Operational Profit

Strong margin improvement

**Operational profitability** (opEBITA/sales)

- **H1 2021 results**
  - 7.5% (in CHF millions)
  - 10.0%

**Sulzer ex APS**

- **Volume:** 17
- **Margin/Mix:** 2
- **OPEX-squeeze reversal:** -17
- **Cost actions:** 23
- **Acquisitions:** 3
- **Δ APS:** 24
- **H1 2021:** 172

July 22, 2021
Operational Profit to EBIT

Low impact from restructuring and other one-off items

(in CHF millions)
EBIT to Net Income

Tax rate normalized with low restructuring expenses

Effective tax rate 24.4%

129
-13
-1
28
86

EBIT H1 21
Financial result
Income from associates
Taxes
Reported net income H1 21
Minorities
Reported net income shareholders H1 21
Core net income H1 21

(in CHF millions)
Free Cash Flow

FCF hitting new record in half-year

(in CHF millions)

<table>
<thead>
<tr>
<th></th>
<th>H1 18</th>
<th>H1 19</th>
<th>H1 20</th>
<th>H1 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>EBITDA</td>
<td>-28</td>
<td>-12</td>
<td>37</td>
<td>117</td>
</tr>
<tr>
<td>Change in Net Working Capital</td>
<td></td>
<td></td>
<td></td>
<td>-18</td>
</tr>
<tr>
<td>Change in non-Net Working Capital</td>
<td></td>
<td></td>
<td></td>
<td>-47</td>
</tr>
<tr>
<td>Total Cashflow from Operating Activities</td>
<td></td>
<td></td>
<td></td>
<td>155</td>
</tr>
<tr>
<td>PP&amp;E Capex</td>
<td></td>
<td></td>
<td></td>
<td>-34</td>
</tr>
<tr>
<td>Purchase of Intangibles</td>
<td></td>
<td></td>
<td></td>
<td>-4</td>
</tr>
<tr>
<td>Free Cashflow</td>
<td></td>
<td></td>
<td></td>
<td>117</td>
</tr>
</tbody>
</table>

**EBITDA to FCF H1 21 (in CHFm)**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>EBITDA</td>
<td>220</td>
</tr>
<tr>
<td>Change in Net Working Capital¹</td>
<td>-18</td>
</tr>
<tr>
<td>Change in non-Net Working Capital²</td>
<td>-47</td>
</tr>
<tr>
<td>Total Cashflow from Operating Activities</td>
<td>155</td>
</tr>
<tr>
<td>PP&amp;E Capex</td>
<td>-34</td>
</tr>
<tr>
<td>Purchase of Intangibles</td>
<td>-4</td>
</tr>
<tr>
<td>Free Cashflow</td>
<td>117</td>
</tr>
</tbody>
</table>

¹ Trade working capital (AR, inventory, AP) up only 5m despite rising sales
² Mainly taxes 44m
Solid balance sheet continues to support selective acquisitions

(in CHF millions)

Balance sheet June 2021:

- Total net debt CHF 557m
- FCF CHF 117m
- Acquisition related payments of 148m in H1
- Ordinary dividend payment of CHF 92m (2021 dividend to Tiwel held back, 43m)
- Tiwel payable now 305m, not interest bearing, no maturity

1. CHF 862m and 2.0x excluding 305m cash held on behalf of Tiwel
Outlook
Financial guidance 2021
As of 22/07/21, adjusted for FX, including acquisitions already closed

- **Sulzer excluding medmix** expects 2021 orders to be up 2-3%, sales up 6-8% and operational profitability to be around 9%, above pre-pandemic level
- **medmix** expects 2021 sales of around CHF 450m and an adjusted EBITDA margin of around 25% (corresponds to around 19% operational profitability)
Spin-off of APS as medmix
Spin-off transaction structure
Symmetrical split for high transparency and corporate governance standards

- Spin-off APS division (to be named medmix going forward) in the form of a symmetrical split\(^1\): Sulzer shareholders get one medmix share in addition to each Sulzer share held
- The split is combined with a CHF200-300m capital increase in medmix with no preferential subscription rights
- As a result of the spin off, Sulzer will retain no material ownership in medmix post transaction
- Listing of APS on Swiss Stock Exchange (SIX) and planned capital increase expected for late Q3 2021 or early Q4 2021 subject to Sulzer shareholder approval at EGM and market conditions

---

\(^1\) according to Art. 31 para. 2 lit. a of the Swiss Merger Act
**Transaction rationale**
Two focused leaders for attractive end-markets

---

**Flow control specialist for water, chemical, industry and energy**
- A global leader in industrial flow control
- Continuous shift towards water and industrial applications in pumps
- Focus on growing biopolymers and recycling markets in separation
- Accelerated growth of services segment

**Innovative, high-precision delivery devices**
- Leading positions in dental, pharma, adhesives and beauty
- Strong own IP innovator across all segments (unlike CMO/CDMOs)
- Attractive mega trends, long-standing customer relationships and lower price sensitivity
- Increasing shift towards high growth healthcare end-markets

---

**Q1 2021 orders**
**CHF 1’551m**

**H1 2021 orders**
**CHF 269m**

---

**Services** 45%
**Chemicals** 18%
**Water** 16%
**Energy** 13%
**Others** 8%

**Healthcare** 38%
**Industry** 36%
**Beauty** 26%
Attractive financial profile with substantial revenue growth and highly resilient margins

- **2021E sales**: CHF 450m
  - ~25% adj. EBITDA margin
- **Healthcare share**: >50%
- **EBITDA margin target**: ~30%
- **8% sales CAGR**
- **Expected leverage post capital increase (net debt / EBITDA)**
  - ~1 – 2x

1 Leverage range reflects a capital increase size of CHF200-300m and EBITDA targets for 2021E
Takeaways

Sulzer

- Positive trend in orders continued in Q2. All divisions growing sequentially
- Q3 likely to be seasonally lower, but expected to show a strong improvement compared to Q3 20 on continued growth in all business segments (except PE Energy) and an acceleration in Service
- Split into two focused companies with different end-markets via a separate stock market listing of medmix
- While medmix will focus on healthcare and further develop its industrial and consumer markets, Sulzer will become a pure play flow control expert with leading market positions and promising sustainable solutions
- Transaction to leverage the full potential of both businesses, providing an attractive value creation opportunity for Sulzer shareholders
- Capital increase of medmix of CHF 200-300m simultaneous with listing planned to reinforce capital structure, fund growth initiatives and increase free float

APS spin-off as medmix
Your Investor Relations contact

Christoph Ladner  
Head of Investor Relations  
Sulzer Management Ltd  
Neuwiesenstrasse 15  
8401 Winterthur  
Switzerland

Phone:  +41 52 262 30 22  
Mobile:  +41 79 326 69 70  
E-mail:  christoph.ladner@sulzer.com